But as healthcare accelerates toward data intensive innovation, mounting pressure on hospital networks is exposing an uncomfortable truth: many are not ready.

In several nephrology indications, this bottleneck is tightening, making early intervention the difference between momentum and delay.

Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the commercialisation of bofanglutide injection in South Korea.

Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn).

Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

RoosterBio has partnered with MineBio Life Sciences to expand access to scalable, research-grade and cGMP-grade MSC solutions across China.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.